These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network. Krick TW; Bressler NM Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861 [TBL] [Abstract][Full Text] [Related]
23. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. Diabetic Retinopathy Clinical Research Network* JAMA Ophthalmol; 2013 Mar; 131(3):283-93. PubMed ID: 23370902 [TBL] [Abstract][Full Text] [Related]
24. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Parravano M; Menchini F; Virgili G Cochrane Database Syst Rev; 2009 Oct; (4):CD007419. PubMed ID: 19821414 [TBL] [Abstract][Full Text] [Related]
25. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. di Lauro R; De Ruggiero P; di Lauro R; di Lauro MT; Romano MR Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):785-91. PubMed ID: 20135139 [TBL] [Abstract][Full Text] [Related]
26. Vascular Endothelial Growth Factor and Diabetic Retinal Disease. Ajlan RS; Silva PS; Sun JK Semin Ophthalmol; 2016; 31(1-2):40-8. PubMed ID: 26959128 [TBL] [Abstract][Full Text] [Related]
27. Systemic and Ocular Adverse Events with Intravitreal Anti-VEGF Therapy Used in the Treatment of Diabetic Retinopathy: a Review. Zehden JA; Mortensen XM; Reddy A; Zhang AY Curr Diab Rep; 2022 Oct; 22(10):525-536. PubMed ID: 36053385 [TBL] [Abstract][Full Text] [Related]
28. Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation. Sinawat S; Rattanapakorn T; Sanguansak T; Yospaiboon Y; Sinawat S Eye (Lond); 2013 Dec; 27(12):1391-6. PubMed ID: 24037235 [TBL] [Abstract][Full Text] [Related]
29. Intraocular pharmacokinetics of anti-vascular endothelial growth factor agents by intraoperative subretinal versus intravitreal injection in silicone oil-filled eyes of proliferative diabetic retinopathy: a randomized controlled pilot study. Yao TT; Yang Y; Jin XL; Wang YX; Zhou YL; Xu AJ; He FL; Wang ZY Acta Ophthalmol; 2020 Nov; 98(7):e795-e800. PubMed ID: 32114709 [TBL] [Abstract][Full Text] [Related]
30. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice. Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA; JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939 [TBL] [Abstract][Full Text] [Related]
31. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. Zhu Y; Zhang T; Xu G; Peng L Cochrane Database Syst Rev; 2016 Dec; 12(12):CD011160. PubMed ID: 27977064 [TBL] [Abstract][Full Text] [Related]
32. Correlation between Diabetic Retinopathy Severity and Oxygen Metabolism in Patients with Diabetic Macular Edema during Treatment with Intravitreal Aflibercept. Blindbæk SL; Peto T; Grauslund J Ophthalmic Res; 2020; 63(2):106-113. PubMed ID: 31715608 [TBL] [Abstract][Full Text] [Related]
34. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Virgili G; Parravano M; Menchini F; Brunetti M Cochrane Database Syst Rev; 2012 Dec; 12():CD007419. PubMed ID: 23235642 [TBL] [Abstract][Full Text] [Related]
35. Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1. Sohn EH; He S; Kim LA; Salehi-Had H; Javaheri M; Spee C; Dustin L; Hinton DR; Eliott D Arch Ophthalmol; 2012 Sep; 130(9):1127-34. PubMed ID: 22965588 [TBL] [Abstract][Full Text] [Related]
36. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951 [TBL] [Abstract][Full Text] [Related]
37. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy. Qian J; Lu Q; Tao Y; Jiang YR Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241 [TBL] [Abstract][Full Text] [Related]